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Letters to the Editors
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compression (and other nonhypoxic reﬂex mechanisms)
actually causes rapid decelerations?6 Should all rapid
decelerations be deﬁned as variable despite the fact that the
decelerations in conﬁrmed cord compression (predominant
chemoreceptor mechanism) have descent time often much
more than 30 seconds with nadir much later than peak of
contractions?6 Could these be some of the most substantial
framing and conﬁrmation fallacies in modern medicine?
The categorization of FHR decelerations is a theoretical/
conceptual framework. If it contradicts careful observations
and critical analysis, then it would be incompatible with the
scientiﬁc method/approach and best be corrected for any
system of CTG interpretation to be meaningful.6
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REPLY
We would like to thank Dr Sholapurkar for his comments
regarding our recent editorial.1 Dr Sholapurkar makes 4
points.
First, Dr Sholapurkar agrees that studies on longitudinal
fetal heart rate (FHR) are desirable, and he believes that such
studies should be retrospective in nature but they may be

problematic if the study methodology is imprecise and subjective. We agree. In our editorial, we emphasized that such
studies can be difﬁcult to perform for a number of reasons
including difﬁculty in choosing the appropriate outcome or
outcomes. To that end, we suggested that cord blood gases at
birth may be a reasonable gold standard, as outcome, and that
the predictor should be the longitudinal FHR changes as
depicted in the ﬁgure of our editorial. We believe that the
longitudinal FHR changes that we described in our editorial,
if used correctly, can remove much of the imprecision and
subjectivity in the methodology of such future studies. We
also would not disregard the beneﬁts of a prospective study
that is designed to rigorously capture information on longitudinal FHR tracing interpretation, clinical context, and
clinical decision making, which are difﬁcult to assess with an
analysis of retrospective data.
The second issue raised by Dr Sholapurkar is that the
distinction between absent and minimal (reduced) FHR
variability may be difﬁcult and clinically unimportant. We
agree and we made this very clear in our editorial. We also
agree that a fetal stimulation test may be helpful in decreasing
false-positive results, but we doubt the value of fetal scalp
blood sampling because this has its own drawbacks and lack
of evidence in improving outcome.2,3
The third point has to do with the clinical signiﬁcance of
postdeceleration overshoots and that FHR decelerations
during the second stage are common and do not warrant
intervention. We agree with the inconclusive evidence about
postdeceleration overshoots. However, we need to make an
important distinction here between the postdeceleration
overshoots and what we emphasized in our editorial, which
was “the rise of FHR baseline with frequent episodes of
tachycardia or continuous tachycardia” in response to
decelerations. We agree that decelerations during the second
stage of labor may not always warrant intervention, but we
should also keep in mind that repetitive prolonged decelerations during the last 30 minutes prior to birth have the
highest predictive ability for fetal acidemia.4
The fourth point is that most babies born with a pH <7.0
have normal FHR variability and that a less strict deﬁnition of
gradual and abrupt for early and variable decelerations,
respectively, may serve us better. It is true that some of the
gradual or abrupt deﬁnitions may not encompass all early or
variable decelerations, but such deﬁnitions correctly identify
the majority of decelerations and at the same time provide
the framework for creating standard nomenclature and
management.
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Efficacy of oral valacyclovir in
cytomegalovirus-infected fetuses
TO THE EDITORS: We read carefully the article of
Leruez-Ville et al1 about the efﬁcacy evaluation of oral
valacyclovir for pregnant women carrying a symptomatic
cytomegalovirus-infected fetus, who are at high risk for
developing both neurosensory and neurological impairments.
Symptomatic fetuses, deﬁned by the presence of measurable
extracerebral or mild cerebral ultrasound signs, were treated
in utero from the prenatal diagnosis, performed at a median
age of 25.9 weeks’ gestation, to the delivery or the termination
of pregnancy. As noted by the authors, high-dosage valacyclovir was effective in improving the outcome of the infected
fetuses. At the interim analysis, 8 of 11 women delivered
asymptomatic neonates that were still asymptomatic at 12
months old.
Over the last decades, the natural history of the cytomegalovirus (CMV) infection in pregnancy has been slightly
changed, being the object of several therapeutic attempts.2
Vaccination is not available and no prenatal treatment of
congenital CMV has yet been validated. The use of
CMV-speciﬁc hyperimmune globulin to prevent vertical
transmission has obtained contrasting results. As suggested,
around 10% of infected neonates are symptomatic at birth
and their risk of sequelae reaches 58%. On the other hand, the
risk of sequelae in asymptomatic newborns is around 13%.2
We understood that the difference in viral load of both
symptomatic and asymptomatic newborns may be critical,
particularly if the predictive value for developing symptoms at
birth in an infected fetus is assessed only by interpreting the
results of both prenatal imaging and laboratory tests.
Increasing the number of data from human studies indicates
that human cytomegalovirus infection interferes with the
differentiation of trophoblast progenitor cells in the human
placenta3 so that the passive immunization with hyperimmune globulin has been shown to reduce viral replication, to
enable the compensatory growth of chorionic villi, to increase
the perfused placental surface, and, for some babies, to
improve the outcome.4
Although this study is not a randomized controlled trial,
this is the ﬁrst one that reports the efﬁcacy of an antiviral

drug in cytomegalovirus-infected fetuses. As a consequence,
this study should encourage new trials using valacyclovir as a
ﬁrst-line safe and effective treatment in CMV-affected pregnant women and comparing this last one with the new
emerging and more potent anticytomegalovirus drugs.
However, based on our evaluation of the study by LeruezVille et al,1 it seems that together with prenatal imaging
and laboratory tests, the infection natural history in symptomatic and asymptomatic neonates could be better predicted
if associated with placenta pathology examination. Once
again we thank the authors for bringing these considerations
to the forefront.
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